It is Necessary to use High Doses of Steroids in the Therapy of Membranous Nephropathy?

M. Rroji, N. Spahia, A. Idrizi, M. Barbullushi, M. Sasdelli
{"title":"It is Necessary to use High Doses of Steroids in the Therapy of Membranous Nephropathy?","authors":"M. Rroji, N. Spahia, A. Idrizi, M. Barbullushi, M. Sasdelli","doi":"10.22259/2639-3573.0101005","DOIUrl":null,"url":null,"abstract":"Idiopathic membranous nephropathy (IMN) has a variable course with frequent spontaneous remission, therefore some authors recommend only non-specific therapy. But in the cases with nephrotic syndrome, the risk of kidney failure is greater in the untreated patients than those who are treated. Various therapeutic schemes proposed in recent years have shown favorable results as a famous Ponticelli regimen, but almost all included the use of immunosuppressants. Although used at low doses, immunosuppressants have the risk of causing long-range tumors over the course of many years. The monotherapy with steroids is not recommended in this nephropathy. We have put in place a therapeutic protocol by usingonly methylprednisolone at low doses to see if it was possible to get a remission of nephrotic syndrome, in order to avoide important side effects. We have treated eleven patients with idiopathic adult membranous nephropathy documented so by renal biopsy and nephrotic syndrome. It was observed a complete remission in 7 patients and a partial remission patients. in 3patients. Onlyone patient did not respond. The follow-up was 17.5 months (3-48 months). In 5 patients total remission persisted after 28.8 months on average (12-48 months). In 2 patients with complete remission and 3 with partial remission, a recurrence of nephrotic syndrome occurred after an average of 6.2 months (3-12 months). These results seem interesting, but before drawing any conclusion, it will be necessary to extend the cases and the follow-up procedure.","PeriodicalId":93415,"journal":{"name":"Archives of nephrology & urology studies","volume":"95 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of nephrology & urology studies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22259/2639-3573.0101005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Idiopathic membranous nephropathy (IMN) has a variable course with frequent spontaneous remission, therefore some authors recommend only non-specific therapy. But in the cases with nephrotic syndrome, the risk of kidney failure is greater in the untreated patients than those who are treated. Various therapeutic schemes proposed in recent years have shown favorable results as a famous Ponticelli regimen, but almost all included the use of immunosuppressants. Although used at low doses, immunosuppressants have the risk of causing long-range tumors over the course of many years. The monotherapy with steroids is not recommended in this nephropathy. We have put in place a therapeutic protocol by usingonly methylprednisolone at low doses to see if it was possible to get a remission of nephrotic syndrome, in order to avoide important side effects. We have treated eleven patients with idiopathic adult membranous nephropathy documented so by renal biopsy and nephrotic syndrome. It was observed a complete remission in 7 patients and a partial remission patients. in 3patients. Onlyone patient did not respond. The follow-up was 17.5 months (3-48 months). In 5 patients total remission persisted after 28.8 months on average (12-48 months). In 2 patients with complete remission and 3 with partial remission, a recurrence of nephrotic syndrome occurred after an average of 6.2 months (3-12 months). These results seem interesting, but before drawing any conclusion, it will be necessary to extend the cases and the follow-up procedure.
膜性肾病是否需要大剂量类固醇治疗?
特发性膜性肾病(IMN)有一个可变的过程,经常自发缓解,因此一些作者只推荐非特异性治疗。但在患有肾病综合征的病例中,未经治疗的患者患肾衰竭的风险比接受治疗的患者要大。近年来提出的各种治疗方案都显示出良好的效果,如著名的Ponticelli方案,但几乎所有方案都包括使用免疫抑制剂。尽管低剂量使用,免疫抑制剂在多年的过程中仍有引起长期肿瘤的风险。这种肾病不推荐单药类固醇治疗。我们已经制定了一个治疗方案,只使用低剂量的甲基强的松龙,看看是否有可能缓解肾病综合征,以避免重要的副作用。我们治疗了11例特发性成人膜性肾病,经肾活检和肾病综合征证实。7例患者完全缓解,1例患者部分缓解。在3例。只有一名患者没有反应。随访17.5个月(3 ~ 48个月)。5例患者总缓解持续时间平均为28.8个月(12-48个月)。2例完全缓解,3例部分缓解,平均6.2个月(3-12个月)后肾病综合征复发。这些结果似乎很有趣,但在得出任何结论之前,有必要扩大病例和后续程序。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信